Drug intelligence / Profile preview

tilapertin

Development stage: Discontinued
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

Tilapertin (AMG 747) is an orally bioavailable, potent, and selective small molecule inhibitor of glycine transporter type-1 (GlyT1). By inhibiting GlyT1, tilapertin increases extracellular glycine concentrations in the central nervous system, which in turn enhances N-methyl-D-aspartate receptor (NMDAR) function. This mechanism is based on the hypothesis that NMDAR hypofunction contributes to negative symptoms in schizophrenia. Tilapertin was developed by Amgen and advanced to phase 2 clinical trials as an adjunctive treatment for negative symptoms of schizophrenia. However, development was terminated after a serious adverse event (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis) occurred during trials[1][2][4][5].

Other names: tilapertin

Targets

SLC6A9 (Glycine transporter type 1)

Beyond the preview

Go deeper on tilapertin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tilapertin.

Explore the full profile